Ozone therapy: the treatment with no authorisation anywhere in the EU
A long commercial history, an unusually blunt American regulation, and claims of national recognition that are hard to trace.
Key takeaways
- No ozone therapy product holds an EU marketing authorisation for any indication.
- The US FDA has stated that ozone has no known useful medical application and is toxic at germicidal concentrations.
- Claims of national recognition are often hard to trace to actual legal instruments.
- The evidence does not support ozone therapy for the conditions it is commonly marketed for.
Medical ozone has been marketed in Europe for the better part of a century, which makes its regulatory status unusually easy to state. There is no EU marketing authorisation for ozone as a medicinal product for any indication, and no harmonised position across member states. It exists in the space that national enforcement reaches unevenly, which is why the same practice can be routine in one country and prosecuted in another.
The United States position is stated more directly than regulators usually manage. A federal regulation records that ozone is a toxic gas with no known useful medical application in specific, adjunctive or preventive therapy, and that in order for ozone to be effective as a germicide it must be present at concentrations far greater than those that can be safely tolerated. Whatever one thinks of it, that is not hedged language.
Greek enforcement history illustrates how this plays out in practice: a 2011 prohibition of an advertising campaign for an ozone device, and six figure consumer protection fines imposed for misleading marketing of ozone treatments. The actions were about claims and advertising rather than about a scientific adjudication, which is the usual pattern where no authorisation exists to revoke.
Against this, trade associations in the field frequently assert that ozone therapy has been regularised or officially recognised in particular countries. These claims are worth taking seriously enough to check, and they are often remarkably difficult to trace to any actual legal instrument; what turns up tends to be a professional society statement, a regional administrative note, or a document that says considerably less than the summary of it. The evidence does not support ozone therapy for any of the conditions it is commonly marketed for, and the absence of authorisation is consistent across the Union rather than an oversight in it.
Notes and sources
Each regulatory statement in this article is set against the document it comes from, so you can read the original rather than our summary of it.
1. No ozone therapy product holds an EU marketing authorisation
2. The definition of a medicinal product and the authorisation requirement
3. Regulatory statement that ozone has no known useful medical application and is toxic
